Review - Intellectual Property

    November 2009

    The Court of First Instance has rejected a combined appeal by GlaxoSmithKline Spa (″GlaxoSmithKline″), Laboratórios Wellcome de Portugal, Lda (″Wellcome″) and The Wellcome Foundation Ltd (″Wellcome Foundation″) (together the ″Applicants″), against decisions of the First Board of Appeal of OHIM for a declaration of invalidity of the Community Trade Mark FAMOXIN on the grounds there was no likelihood of confusion by the public with the earlier registered mark LANOXIN.